Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 147266-79-3 | MDL No. : | MFCD06656447 |
Formula : | C16H21NO5 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | IQFZJNCETIGXIO-STQMWFEESA-N |
M.W : | 307.34 | Pubchem ID : | 2756009 |
Synonyms : |
|
Num. heavy atoms : | 22 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.5 |
Num. rotatable bonds : | 6 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 84.38 |
TPSA : | 76.07 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.33 cm/s |
Log Po/w (iLOGP) : | 2.7 |
Log Po/w (XLOGP3) : | 2.6 |
Log Po/w (WLOGP) : | 2.15 |
Log Po/w (MLOGP) : | 1.53 |
Log Po/w (SILICOS-IT) : | 1.11 |
Consensus Log Po/w : | 2.02 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -3.19 |
Solubility : | 0.199 mg/ml ; 0.000647 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.85 |
Solubility : | 0.0437 mg/ml ; 0.000142 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.38 |
Solubility : | 1.28 mg/ml ; 0.00416 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.5 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
58% | With sodium hydroxide In tetrahydrofuran | (Step 2) Synthesis of (2S,4S)-1-tert-butoxycarbonyl-4-phenoxy-2-pyrrolidinylcarboxylic acid To a solution of methyl (2S,4S)-1-tert-butoxycarbonyl-4-phenoxy-2-pyrrolidinylcarboxylate (5.31 g, 16.5 mmol) in THF (132 ml) was added 0.25N NaOH (132 ml, 33.0 mmol). The reaction mixture was stirred overnight at room temperature. The residue obtained by concentrating the reaction mixture under reduced pressure was acidified with 1N HCl, followed by extraction with chloroform. The extract was washed with saturated brine, dried over anhydrous sodium sulfate and distilled under reduced pressure to remove the solvent. The crude crystals thus obtained were recrystallized from hexane-chloroform, whereby the title compound (2.96 g, 58percent) was obtained as a white crystalline powder. 1H-NMR (DMSO-d6) δ: 1.36 (s, 9H), 2.16 (d, J=13.2Hz, 1H), 2.56 (m, 1H), 3.46 (m, 1H), 3.71 (dt, J=12.0,5.4Hz, 1H), 4.26 (dt, J=9.5,7.1Hz, 1H), 4.99 (m, 1H), 6.85 (m, 2H), 6.94 (t, J=7.3Hz, 1H), 7.28 (t, J=7.3Hz, 1H). |
[ 1161602-22-7 ]
1-(Phenoxycarbonyl)pyrrolidine-2-carboxylic acid
Similarity: 0.85